Immediate Post-Needlestick HIV Exposure Management

Introduction to PEP

The American College of Occupational and Environmental Medicine and other guideline societies recommend starting HIV post-exposure prophylaxis (PEP) immediately, ideally within the first hour and absolutely within 72 hours, using a 28-day course of combination antiretroviral therapy, even before confirming the patient's HIV status, with high strength of evidence 1, 2

The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) advise washing the exposure site thoroughly with soap and water immediately, without squeezing or applying pressure to increase bleeding, as part of the initial management 3, 1
The Occupational Safety and Health Administration (OSHA) recommends reporting the incident to your supervisor immediately and documenting the exposure details, including date, time, type of device, and extent of injury, to ensure timely medical evaluation and treatment 3, 1
Seeking emergency medical evaluation within 1 hour to initiate PEP is crucial, as the sooner PEP is started, the more effective it is, with effectiveness dropping dramatically after 72 hours, according to the CDC and WHO 2

The actual risk of HIV transmission from a percutaneous needlestick with HIV-infected blood is approximately 0.3-0.36% (3-4 per 1,000 exposures), but PEP reduces this risk by approximately 81% when started promptly, as reported by the CDC and the National Institute for Occupational Safety and Health (NIOSH) 1, 2
The risk of hepatitis B transmission without prophylaxis can exceed 30%, and the risk of hepatitis C transmission is about 1.8%, highlighting the importance of prompt testing and management, according to the CDC and the WHO 1

The CDC recommends an HIV antibody test (rapid testing preferred) as part of the initial testing protocol for the source patient, to expedite PEP decisions 1
Testing for hepatitis B surface antigen (HBsAg) and hepatitis C antibody (anti-HCV) is also recommended for the source patient, as per the CDC and WHO guidelines 3, 1
Baseline testing for the exposed individual should include HIV antibody or antigen/antibody combination test, hepatitis B serology, and hepatitis C antibody (anti-HCV), with a pregnancy test if applicable, according to the CDC and the American College of Obstetricians and Gynecologists (ACOG) 1, 2

The CDC and the WHO recommend preferred antiretroviral combinations, including bictegravir/emtricitabine/tenofovir alafenamide (single tablet once daily) or dolutegravir plus tenofovir alafenamide or tenofovir disoproxil fumarate plus emtricitabine or lamivudine, with a high strength of evidence 2
Completing the full 28-day course of PEP is essential, as stopping early eliminates protection, according to the CDC and the WHO 2

The CDC recommends hepatitis B immune globulin (HBIG) immediately and starting the hepatitis B vaccine series if the exposed individual is unvaccinated or incompletely vaccinated and the source is HBsAg-positive, with a moderate strength of evidence 3, 1
For hepatitis C, there is no post-exposure prophylaxis, and early identification through testing is the primary approach, according to the CDC and the WHO 1

The CDC advises using barrier protection during sexual activity for 6 months post-exposure and not donating blood, plasma, organs, tissue, or semen during the follow-up period, with a high strength of evidence 1
Seeking immediate medical evaluation for any acute illness during follow-up is recommended, as these may indicate acute retroviral syndrome, according to the CDC and the WHO 1

The Centers for Disease Control and Prevention recommends washing the exposed area thoroughly with soap and water, and flushing immediately with clean water or saline if blood splashed into eyes, nose, or mouth 4
The CDC suggests documenting the time of exposure immediately, as timing is critical for PEP effectiveness, and evaluating the condition of the skin (intact vs non-intact) 4

The CDC recommends HIV testing at 6 weeks, 3 months, and 6 months post-exposure, and hepatitis C testing at 4-6 months, with consideration of HCV RNA at 4-6 weeks for earlier diagnosis 4
The CDC advises monitoring for drug toxicity every 2 weeks during PEP, and evaluating within 72 hours of starting PEP 4

The CDC recommends seeking immediate medical evaluation for any acute illness during the 6-month follow-up period, which may indicate acute retroviral syndrome 4
The CDC suggests documenting the date and time of exposure, type of fluid, condition of skin, source patient HIV status, and all interventions and timing 4